ICD-10 Codes for Endometrial Adenocarcinoma: A Comprehensive Guide

Endometrial adenocarcinoma is a type of cancer that develops in the lining of the uterus. It is the most common type of uterine cancer, accounting for about 90% of cases. The International Classification of Diseases, 10th Revision (ICD-10) provides codes for endometrial adenocarcinoma, which are used to identify and track the disease for statistical and research purposes.

ICD-10 Codes for Endometrial Adenocarcinoma

The ICD-10 codes for endometrial adenocarcinoma are as follows:

Epidemiology of Endometrial Adenocarcinoma

Endometrial adenocarcinoma is the most common gynecological cancer in the United States, with an estimated 65,620 new cases and 12,500 deaths in 2023. The incidence of endometrial adenocarcinoma has been increasing in recent years, and it is now the fourth leading cause of cancer death among women in the United States.

The risk of endometrial adenocarcinoma increases with age, and most cases occur in women over the age of 50. Other risk factors for endometrial adenocarcinoma include obesity, diabetes, hypertension, and estrogen replacement therapy.

Symptoms of Endometrial Adenocarcinoma

The most common symptom of endometrial adenocarcinoma is vaginal bleeding after menopause. Other symptoms may include:

• Pelvic pain
• Vaginal discharge
• Painful intercourse
• Bloating
• Weight loss

Diagnosis of Endometrial Adenocarcinoma

Endometrial adenocarcinoma is diagnosed with a biopsy, which is a procedure in which a sample of tissue is removed from the uterus and examined under a microscope. A biopsy may be performed during a pelvic exam or in a separate procedure called a hysteroscopy.

Treatment of Endometrial Adenocarcinoma

The treatment of endometrial adenocarcinoma depends on the stage of the disease. Treatment options may include surgery, radiation therapy, chemotherapy, and hormone therapy.

Prognosis of Endometrial Adenocarcinoma

The prognosis of endometrial adenocarcinoma depends on the stage of the disease at the time of diagnosis. The five-year survival rate for endometrial adenocarcinoma is about 80%. However, the survival rate decreases with increasing stage.